BPC-157 Dosage Guide
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Dosage overview
| Typical dose | 250-500 mcg per day (subcutaneous injection); some protocols use up to 750 mcg per day |
| Frequency | Once or twice daily — injectable administered subcutaneously, oral taken on empty stomach |
| Cycle length | 4-8 weeks on, followed by a similar off period |
Dosing notes
Most research protocols administer BPC-157 via subcutaneous injection, either near the injury site for localized conditions or in the abdominal area for systemic effects. Studies suggest that local injection near an injured tendon or muscle may produce faster localized results, while abdominal injection distributes the compound systemically. Oral administration has shown efficacy for gastrointestinal conditions in animal models, where local exposure in the GI tract is the primary mechanism. For systemic musculoskeletal effects, injectable forms are more commonly studied and reported as more effective. The standard acetate salt form has low oral bioavailability in standard form. The arginate salt form reportedly demonstrates significantly higher oral absorption, though peer-reviewed bioavailability comparisons are not available. Reconstitution for injectable use: a standard 5mg vial mixed with 2mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. At this concentration, 10 units on a standard insulin syringe (U-100) equals 250 mcg. Storage: lyophilized (powder) form remains stable for years when stored below -18C. Once reconstituted with bacteriostatic water, store refrigerated at 2-8C and use within 4-6 weeks. If reconstituted with sterile water without preservative, use within 5-7 days refrigerated. BPC-157 is not FDA-approved for human use. It was placed in FDA Category 2 in 2023, meaning it does not meet current safety criteria for pharmacy compounding. All dosing information reflects research protocols and community-reported practices, not medical recommendations.
Important safety information
Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.
- Start at the lowest effective dose and titrate up gradually
- Monitor for side effects, especially during dose increases
- Do not exceed researched dose ranges without medical supervision
- This is a research compound — human dosing guidelines are not FDA-established
Interactive protocol guide
Step-by-step: your dosing schedule with exact syringe units, what supplies to buy, how to mix, and how to inject.
BPC-157 Protocol Overview
Goal
Tissue repair
Duration
8 weeks
Route
subcutaneous
Important before you start:
- BPC-157 is a research peptide with no FDA approval. Human clinical trial data is limited.
- Inject as close to the injury site as practical for best results.
- Discontinue if you notice any unusual swelling, redness, or warmth at the injection site.
Your dosing schedule
Based on a 5 mg vial mixed with 2 mL bacteriostatic water (2.50 mg/mL concentration). Using a U-30 insulin syringe.
Draw to here
3 units
on 30-unit syringe
1-8: 250 mcg
| When | Dose | Syringe units | Frequency | What to expect |
|---|---|---|---|---|
| 1-8 | 250 mcg | 3 units | Once daily | Flat dose for the full 8-week cycle. Inject near the injury site if possible. |
1-8: 250 mcg
Flat dose for the full 8-week cycle. Inject near the injury site if possible.
What you need for a 8-week BPC-157 protocol
BPC-157 vials (5 mg each)
Quantity: 3
Bacteriostatic water (30 mL vial)
Quantity: 1
Insulin syringes (U-30, 29ga)
Quantity: 56+ (one per injection, never reuse)
Alcohol prep pads
Quantity: 112+ (one for vial, one for skin)
Sharps container
Quantity: 1
Quantities based on 8-week protocol using 5 mg vials reconstituted with 2 mL BAC water each.
How to mix your BPC-157
Your concentration:
5 mg peptide + 2 mL water = 2.50 mg/mL (2500 mcg/mL)
- 1
Wash your hands
Wash with soap and water for 30 seconds. Dry completely.
- 2
Clean the vial tops
Wipe the rubber stopper on your BPC-157 vial AND your bacteriostatic water vial with an alcohol swab. Let air dry for 10 seconds.
- 3
Draw 2 mL of bacteriostatic water
Using an insulin syringe, draw 2 mL (60 units on a U-30 syringe) of bacteriostatic water.
- 4
Inject water into the BPC-157 vial
Hold the peptide vial at a 45-degree angle. Point the needle at the WALL of the vial, NOT directly onto the powder. Push the plunger slowly over 10-15 seconds. Let the water run down the inside wall.
- 5
Swirl gently to dissolve
Swirl the vial in a slow circular motion for 30-60 seconds. NEVER shake. If not fully dissolved, let it sit for 2-5 minutes and swirl again.
- 6
Refrigerate immediately
Store reconstituted peptide at 36-46 degrees F (2-8 degrees C). Good for 4-6 weeks refrigerated. Label the vial with the date you mixed it.
Common mistakes that ruin your peptide:
- Shaking the vial (breaks peptide bonds, reduces potency 30-50%)
- Spraying water directly on the powder (damages the peptide)
- Using sterile water instead of bacteriostatic water (no preservative, short shelf life)
- Leaving mixed peptide at room temperature (loses 10-20% potency per day)
How to inject BPC-157
Timing: Morning or pre-workout
- 1Choose your injection site and rotate each time (at least 1 inch from the last site).
- 2Wipe the injection site with an alcohol prep pad. Let air dry completely.
- 3Draw your dose (check the dosing schedule above for exact syringe units).
- 4Pinch a fold of skin at the injection site.
- 5Insert the needle at a 45-90 degree angle into the pinched skin fold.
- 6Push the plunger slowly and steadily.
- 7Release the skin fold, then withdraw the needle.
- 8Do NOT rub the injection site. Light pressure with a cotton ball is fine if there is any blood.
- 9Dispose of the syringe immediately in your sharps container. Never recap or reuse.
Site rotation tip
Divide your preferred injection area into a mental grid. Move to a new spot each injection. For Near injury site and Abdomen and Thigh injections, alternate between sides (left/right) each time.
Research references
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS Journal (2025) [PubMed]
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Alternative Therapies in Health and Medicine (2025) [PubMed]
- Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds — Regulatory Toxicology and Pharmacology (2020) [PubMed]
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — Journal of Molecular Medicine (2017) [PubMed]
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth — Journal of Orthopaedic Research (2003) [PubMed]
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Journal of Applied Physiology (2011) [PubMed]
- Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — Medical Science Monitor (2010) [PubMed]
- Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation — Bone (1999) [PubMed]
- Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice — Burns (2001) [PubMed]
- Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro — Drug Design, Development and Therapy (2015) [PubMed]
- Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration: a comparative study with dopamine agonists and somatostatin — Life Sciences (1993) [PubMed]
- Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats — Collegium Antropologicum (2005) [PubMed]
- Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway — Scientific Reports (Nature) (2020) [PubMed]
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Current Pharmaceutical Design (2011) [PubMed]
- Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — Life Sciences (2011) [PubMed]
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.